Obalon Therapeutics explores strategic alternatives as coronavirus hits

(Reuters) – Obalon Therapeutics said on Wednesday it was exploring financial and strategic alternatives due to the uncertainty regarding COVID-19 and restriction on elective procedures, which have had a direct impact on its business.

The company has engaged Canaccord Genuity LLC as its financial advisor.

Reporting by Trisha Roy in Bengaluru; Editing by Vinay Dwivedi

Our Standards:The Thomson Reuters Trust Principles.

Visit the Source Site

Powered by WPeMatico